By univariate analysis, an inferior clinical outcome was related to IPI >2 [Hazard Ratio (HR) 2.90, P<0.001], Prognostic Index for PTCL-unspecified (PIT)[28] >2 (HR 3.29, P<0.001), the male sex (HR 1.60, P = 0.016), the lack of a clinical response to primary treatment (HR 6.61, P<0.001), PTCL not otherwise specified (NOS) histology compared with ALCL ALK positive (HR 2.54, P<0.001) and MACOP-B treatment (HR 0.59, P = 0.040) while year of treatment >2003 (HR 1.32, P = 0.153) did not show any impact. This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.